Introduction
============

For patients with colorectal cancer liver metastasis, hepatic resection is the main curative choice (CRLM)[@B1]. However, approximately 75% of patients experience tumor recurrence after the first liver resection[@B2], and only 16% of patients remain disease-free for 10 years after hepatectomy[@B3]. Therefore, identifying efficient prognostic factors is urgently needed to screen for high-risk subgroups and subsequently to optimize therapeutic interventions to achieve maximum therapeutic effectiveness.

Many studies have demonstrated that the progression of cancer is determined not only by tumor features but also by nutritional and immunological conditions[@B4]-[@B6]. The prognostic nutritional index (PNI), which is calculated according to serum albumin levels and peripheral lymphocyte numbers, reflects both the nutritional and immune status of the patient[@B7]. To date, some studies have demonstrated that the PNI is an indicator that could predict patients\' prognosis for various malignancies, including hepatocellular carcinoma[@B8], renal cell carcinoma[@B9], pancreatic cancer[@B10], and gastric carcinoma[@B11]. However, to our knowledge, no studies have focused on the predictive role of PNI as an effective indicator of the prognosis of CRLM patients who are undergoing curative hepatic resection. In addition, the optimal cut-off value of PNI for the prediction of oncologic outcomes remains controversial. In this study, we aimed to identify the optimal PNI cut-off value and to investigate the prognostic impact of the preoperative PNI in patients with CRLM who are undergoing curative hepatic resection.

Materials and Methods
=====================

Patients
--------

We reviewed the medical records of CRLM patients who underwent hepatic resection from September 1999 to July 2015. From the 355 cases identified, we excluded patients with palliative resection of primary tumors (n=15) and palliative resection of liver metastases (n=35) as well as those missing preoperative data, which would make it impossible to calculate the PNI (n=62). Finally, 243 CRLM patients were included in the study. The enrolled patients met the following inclusion criteria: 1) histologically confirmed colorectal adenocarcinoma, 2) metastases to the liver, and 3) R0 resection for both the primary tumor and the liver metastases. The patient demographics, the primary and metastatic tumor characteristics, the perioperative treatment, and the follow-up results were reviewed in detail from the medical records and the follow-up system of the Sun Yat-sen University Cancer Center. All the procedures performed in studies involving human participants were in accordance with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Institutional review board approval was also obtained from the independent ethics committee at the Sun Yat-sen University Cancer Center. Informed consent was waived in this noninterventional, observational, and retrospective study, in which the patient data were kept strictly confidential.

Systemic inflammation markers
-----------------------------

Blood samples were collected from the patients no more than 7 days prior to the hepatic operation and analyzed for the complete blood count with differential and blood chemistry tests including albumin, tumor markers including carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA199), and other laboratory tests. The PNI was calculated as 10× the serum albumin concentration (g/dL) + 0.005 × the total lymphocyte count (per mm^3^). There was no validated cut-off value for the PNI from the previous studies, so the optimal cut-off value used for the PNI in this study was calculated by the X-tile software.

Follow-up
---------

All patients received the recommendation to return for subsequent visits every 3 months for 2 years after being discharged from the hospital, followed by semi-annual visits for an additional year. The follow-up evaluation included a routine blood test, analysis of the levels of CEA and CA19-9, abdominal ultrasonography, and chest radiograph. Chest computed tomography, abdominal/pelvic magnetic resonance imaging, and colonoscopy were performed annually. Overall survival (OS) was defined as the duration from the hepatic resection to death from any cause, while recurrence-free survival (RFS) was defined as the time interval between hepatic resection to disease recurrence or death. The follow-up period was terminated in December 2017.

Statistical analysis
--------------------

Continuous variables are represented as the median (range) or the mean (standard deviation), and categorical variables are represented as percentages. The X-tile 3.6.1 software (Yale University, New Haven, CT, USA) was used to determine the optimal cut-off value of PNI, which was identified from the minimum P value according to the OS. Statistical analyses were performed using SPSS 20.0 software (IBM, Chicago, IL, USA) and GraphPad Prism 7 software (GraphPad Software, Inc, San Diego, CA, USA). We compared continuous variables that were normally distributed using Student\'s t test and compared categorical variables using the chi-square (χ^2^) test, Fisher\'s test or the nonparametric Mann-Whitney U test. Survival outcomes were calculated with the Kaplan-Meier method, and the statistical significance was compared using the log-rank test. Variables that were statistically significant with a P\<0.05 in univariate Cox models were further assessed with multivariate Cox models using a forward stepwise method. The multivariate Cox proportional hazard model was used to further identify the independent prognostic factors for RFS and OS. Hazard ratios (HRs) and 95% confidence intervals (CI) were calculated. A P value less than 0.05 was considered statistically significant.

Results
=======

Optimal cutoff value of PNI
---------------------------

X-tile software was used to determine 48.5 as the optimal cut-off value for the PNI, which was identified from the minimum P value according to the OS (Figure [1](#F1){ref-type="fig"}). In the subsequent analysis, the PNI values were divided into low-level (≤48.5) and high-level (\>48.5) groups according to the PNI before hepatic resection.

Patient characteristics
-----------------------

A total of 243 CRLM patients who underwent curative liver resection were analyzed in this study. The median age of the patients was 56 years (range, 25-82 years). Of the total patients, there were 151 (62.1%) men and 92 (37.9%) women; 154 (63.4%) patients had colon cancer, and 89 (36.6%) patients had rectal cancer. In 138 (56.8%) patients, the primary tumors involved lymph node metastasis. Most patients (172/243, 70.8%) had synchronous liver metastases at the time of initial diagnosis. For the hepatic metastases, the median size of the largest tumor was 3.0 cm (range 0.3-12.0 cm). In addition, 125 (51.4%) patients received synchronous resection for the primary tumor and the liver metastases. With respect to chemotherapy, 78 (32.1%) patients received neoadjuvant chemotherapy before the hepatectomy, and 184 (75.7%) patients received postoperative chemotherapy. The detailed clinical and pathological characteristics of all included patients are shown in Table [1](#T1){ref-type="table"}.

Association between PNI and clinicopathological features
--------------------------------------------------------

The associations between the PNI status and various clinicopathological features are shown in Table [2](#T2){ref-type="table"}. Among all 243 patients, there were no significant differences in the distribution of sex, tumor location or TN stage between the two groups. Additionally, patients in the two groups had similar sizes of primary tumors and liver metastases as well as similar numbers of liver metastases. Moreover, there were no significant differences in the histological grade, CEA level, or CA199 level of the patients in the low- and high-PNI groups. Older patients (age \>60 years) and those who received synchronous hepatic resection were more frequently observed in the low-PNI group (P=0.023 and P=0.001).

Association between PNI and survival
------------------------------------

During the follow-up period, the median OS times for the patients in the high-PNI and low-PNI groups were 95.7 months and 48.5 months, respectively. In addition, the median follow-up time after liver surgery was 36.6 months (range, 0.3-145.4 months). At the last follow-up, 107 (44.0%) patients had died. The 1-, 3-, and 5-year OS rates were 92.9%, 65.6%, and 52.1%, respectively. The relationships between the PNI and the survival outcomes are presented in Fig. [2](#F2){ref-type="fig"}. A low PNI value was associated with poor OS (P=0.01, shown in Figure [2](#F2){ref-type="fig"}A). The 1-, 3-, and 5-year OS rates were 87.6%, 55.7%, and 39.6% in the low-PNI group, respectively, and 96.0%, 70.8%, and 57.4% in the high-PNI group, respectively. Furthermore, patients in the high-PNI group had longer RFS times than those in the low-PNI group (P=0.045, shown in Figure [2](#F2){ref-type="fig"}B). In the patients from the low-PNI group, the 1-, 3-, and 5-year RFS rates were 57.3%, 33.0%, and 26.1%, respectively, compared with 66.4%, 41.7%, and 36.5%, respectively, in the high-PNI group.

The univariate analysis revealed that a high PNI value was associated with longer OS (HR=0.606; 95% CI=0.412-0.890; P=0.011) and RFS (HR=0.725; 95% CI=0.528-0.995; P=0.046), as shown in Table [3](#T3){ref-type="table"}. In contrast, lymph node metastases, multiple liver metastases and undergoing radiofrequency ablation (RFA) therapy were correlated with shorter RFS and OS. Additionally, older patients and those who did not receive chemotherapy after hepatic resection had shorter OS times. Patients with larger liver metastases, higher CEA level, or chemotherapy before hepatic resection had shorter RFS. An additional Cox multivariate analysis indicated that low PNI was a nagative independent prognostic factor for OS (HR = 0.574, 95% CI = 0.387-0.851, P =0.006 Table [3](#T3){ref-type="table"}) and RFS (HR =0.650, 95% CI = 0.472-0.897, P =0.009). In addition, lymph node metastases, multiple liver metastases and RFA therapy were all independent predictors of poor OS and RFS for patients with CRLM who underwent hepatic resection. In addition, patients who received no chemotherapy after hepatic resection had worse OS, and those with higher CEA levels had worse RFS (Table [3](#T3){ref-type="table"}).

Discussion
==========

The preoperative nutritional and immunological conditions of patients have been found to be associated with both the surgical and oncologic outcomes of malignant tumors[@B6]. Recently, various indices containing nutritional and inflammatory parameters have been introduced to predict surgical risks and oncologic outcomes[@B12]-[@B14]. Among them, the PNI, a simple and useful systemic inflammation-based prognostic score, is calculated based on laboratory assessments of total lymphocyte counts and serum albumin levels and can reflect the host immunological and nutritional status[@B7]. Low PNI scores were first found to be predictive of a high risk of short-term postoperative complications in the gastrointestinal tract. Recently, increasing evidence has revealed that low PNI scores are also related to reduced survival in various types of malignant tumors[@B10], [@B11], [@B15]. However, few studies have investigated the significance of PNI as a prognostic factor for survival in CRLM patients who have undergone curative liver resection. In this retrospective study, we investigated the clinical significance of preoperative PNI scores in 243 patients with CRLM who underwent curative liver resection. The results showed that low PNI scores were associated with older age of the patient. In addition, low PNI scores were more likely to be observed in patients who underwent synchronous hepatic resection. We also demonstrated the association of preoperative PNI scores with oncologic outcomes. From the multivariate analysis, the PNI score was a negative independent predictor for both OS and RFS in CRLM patients who underwent curative liver resection.

Several nutritional and immunological parameters have been identified as being useful for the prediction of cancer patients\' prognoses [@B16]-[@B19]. Among these, the PNI has been widely used because of its efficiency, simplicity, and convenience for clinical work. The PNI has been used to assess the preoperative condition of and to predict the surgical risk for gastrointestinal malignancy patients[@B7]. It is calculated based on only two factors, namely the serum albumin concentration and the lymphocyte count in the peripheral blood. The PNI was first suggested to be a nutritional index and a predictor of surgical risk, and this result was further verified by another study[@B8], [@B10]. Since then, numerous recent studies have demonstrated that a low PNI score is an independent adverse prognostic factor for short-term postoperative complications and long-term outcomes in many kinds of cancer. As is well known, the prognoses of cancer patients rely on a number of clinicopathological factors, such as TNM stage and histological type. PNI scores, however, have also been found to be closely correlated with cancer prognosis in certain types of cancer. Therefore, theoretically, PNI scores should be associated with some of those clinicopathological characteristics. In our study, we found that older patients (age \>60 years) and those who received synchronous hepatic resection were more frequently observed in the low-PNI score group.

As a prognostic indicator, preoperative PNI has the advantage of being easily acquired because the serum albumin level and the total lymphocyte count are basic parameters that are assessed before surgery. However, an accurate cut-off value of PNI scores to use to group patients has not been determined. In a variety of malignancies, the cut-off value was determined as a wide range of 40-51[@B9], [@B20]-[@B24]. The same situation exists in colorectal cancer (CRC), for which a uniform cut-off value has not been established, with each study presenting a different value[@B16], [@B25]-[@B28]. Tokunaga et al. found that the optimal cut-off value of PNI was 45.5 using classification and regression tree analysis for OS[@B28]. Jian-hui et al. established the cut-off value as 45 according to receiver operating characteristic curve (ROC) curve analysis[@B25]. In our large cohort study, with the help of X-tile software using the OS of CRLM patients who underwent curative hepatic resection, we found that the optimal cut-off value for preoperative PNI scores was 48.5. PNI scores ≤48.5 were defined as the low-PNI group, and scores \>48.5 were defined as the high-PNI group. By classifying patients with this cut-off value of 48.5, significant differences in RFS and OS were observed in the present study. In clinical work, with the help of a PNI score cut-off value, we can group CRLM patients into 2 categories. Patients with high PNI scores (\>48.5) may have a relatively poor survival compared to those with low PNI scores (≤48.5). When patients with low PNI scores have two options for therapeutic regimens, they can choose the less aggressive option as the optimal one. In addition, these patients can consider undertaking a less strict follow-up schedule, considering the cost of follow-up examinations.

This study has some limitations. First, it was a retrospective study with data collected from a single institution, so potential inaccuracies may have occurred during the documentation of the medical records. However, the larger sample size provided adequate statistical power to explore the association of preoperative PNI scores with oncologic outcomes. Another limitation was the relatively short median follow-up period. However, because approximately 75% of patients experience recurrence within 2 years, the median follow-up duration of 36.6 months after hepatic resection based on clinical practice was not regarded as short. Last, it was retrospective in design. The timing of the preoperative total lymphocyte counts and the serum albumin level measurements was not always the same, which could bias the results. However, we attempted to measure both parameters within a 1-week timeframe before liver surgery.

The present study demonstrated that preoperative PNI scores with a cut-off value of 48.5 constituted a simple and efficient indicator to estimate the survival of CRLM patients who underwent curative hepatic resection. Older patients (age \>60 years) and those who received synchronous hepatic resection were more likely to have lower preoperative PNI scores. A high preoperative PNI score is an independent prognostic factor for poor oncologic outcome including the OS and RFS of patients with CRLM undergoing hepatic resection.

We would like to acknowledge the patients who participated in this study. We also gratefully acknowledge the assistance of the colleagues at State Key Laboratory of Oncology in South China and the Department of Colorectal Surgery in Sun Yat-sen University Cancer Center. The authenticity of the data in this article has been validated by uploading the key raw data onto the Research Data Deposit public platform ([www.researchdata.org.cn](http://www.researchdata.org.cn)), with the approval number as RDDB2018000298.
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![The X-tile plots of the PNI and the OS of CRLM patients who underwent curative hepatic resection. The X-tile plots show the χ^2^ values with cut-off values, generating the low- and high-PNI subgroups. **A** X-tile plots of PNI expression for optimal cutoff point, which is demarcated by a black circle. **B** The histogram of the entire cohort divided into low-PNI and high-PNI subgroups according to the optimal cut-off value of 48.5. **C** Kaplan-Meier plot of survival rates in groups stratified by the optimal cut-off value of the PNI. Blue represents the low-PNI group, and gray represents the high-PNI group.](jcav09p2167g001){#F1}
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###### 

Clinicopathologic features of patients involved in this study.

  ------------------------------------------------------------------------------------
  Characteristics                                                         Total\
                                                                          n=243 (%)
  ----------------------------------------------- ----------------------- ------------
  Age (years)                                     ≤60                     152 (62.6)

                                                  \>60                    91 (37.4)

  Sex                                             Female                  92 (37.9)

                                                  Male                    151 (62.1)

  Primary tumor site                              Colon                   154 (63.4)

                                                  Rectum                  89 (36.6)

  Primary tumor size (cm)                         ≤4                      114 (46.9)

                                                  \>4                     79 (32.5)

                                                  Not available           50 (20.6)

  T stage                                         1                       2 (0.8)

                                                  2                       18 (7.4)

                                                  3                       139 (57.2)

                                                  4                       84 (34.6)

  N stage                                         0                       105 (43.2)

                                                  1                       80 (32.9)

                                                  2                       58 (23.9)

  Histological grade                              Well/moderate           208 (85.6)

                                                  Poor                    35 (14.4)

  Size of liver metastases (cm)                   ≤2.5                    131 (53.9)

                                                  \>2.5                   112 (46.1)

  Number of liver metastases                      Single                  117 (48.1)

                                                  Multiple                126 (51.9)

  Extrahepatic metastasis                         Yes                     21 (8.6)

                                                  No                      222 (91.4)

  Hepatic resection timing                        Metachronous            118 (48.6)

                                                  Synchronous             125 (51.4)

  Chemotherapy regimen before hepatic resection   Including irinotecan    19 (7.8)

                                                  Including oxaliplatin   55 (22.6)

                                                  Others                  4 (1.6)

                                                  No chemotherapy         165 (67.9)

  Chemotherapy regimen after hepatic resection    Including irinotecan    46 (18.9)

                                                  Including oxaliplatin   125 (51.4)

                                                  Others                  13 (5.3)

                                                  No chemotherapy         59 (24.3)

  RFA therapy ^a^                                 Yes                     28 (11.5)

                                                  No                      215 (88.5)

  CEA level (ng/ml) ^b^                           ≤5                      95 (39.1)

                                                  \>5                     148 (60.9)

  CA19-9 level (U/ml) ^c^                         ≤37                     174 (71.6)

                                                  \>37                    69 (28.4)
  ------------------------------------------------------------------------------------

^a^ Radiofrequency ablation therapy within 3 months before or after hepatic resection

^b^ Carcinoembryonic antigen before hepatic resection

^c^ Cancer antigen 19-9 before hepatic resection

###### 

Relationships between PNI and patient characteristics

  Characteristics                                 PNI (n=243)                
  ----------------------------------------------- ------------- ------------ -------
  Age (years)                                                                
  ≤60                                             48 (53.3)     104 (68.0)   0.023
  \>60                                            42 (46.7)     49 (32.0)    
  Sex                                                                        
  Female                                          30 (33.3)     62 (40.5)    0.265
  Male                                            60 (66.7)     91 (59.5)    
  Primary tumor site                                                         
  Colon                                           59 (65.6)     95 (62.1)    0.588
  Rectum                                          31 (34.4)     58 (37.9)    
  Primary tumor size (cm) ^a^                                                
  ≤4                                              40 (44.4)     74 (48.4)    0.101
  \>4                                             37 (41.1)     42 (27.5)    
  Not available                                   13 (14.4)     37 (24.2)    
  T stage                                                                    
  1-3                                             62 (68.9)     97 (63.4)    0.385
  4                                               28 (31.1)     56 (36.6)    
  N stage                                                                    
  0                                               39 (43.3)     66 (43.1)    0.976
  1-2                                             51 (56.7)     87 (56.9)    
  Histological grade                                                         
  Well/moderate                                   75 (83.3)     133 (86.9)   0.441
  Poor                                            15 (16.7)     20 (13.1)    
  Size of liver metastases (cm)                                              
  ≤2.5                                            50 (55.6)     81 (52.9)    0.693
  \>2.5                                           40 (44.4)     72 (47.1)    
  Number of liver metastases                                                 
  Single                                          46 (51.1)     71 (46.4)    0.478
  Multiple                                        44 (48.9)     82 (53.6)    
  Extrahepatic metastasis                                                    
  Yes                                             7 (7.8)       14 (9.2)     0.713
  No                                              83 (92.2)     139 (90.8)   
  Hepatic resection timing                                                   
  Metachronous                                    31 (34.4)     87 (56.9)    0.001
  Synchronous                                     59 (65.6)     66 (43.1)    
  Chemotherapy regimen before hepatic resection                              
  Yes                                             32 (35.6)     46 (30.1)    0.376
  No                                              58 (64.4)     107 (69.9)   
  Chemotherapy regimen after hepatic resection                               
  Yes                                             63 (70.0)     121 (79.1)   0.111
  No                                              27 (30.0)     32 (20.9)    
  RFA therapy ^b^                                                            
  Yes                                             10 (11.1)     18 (11.8)    0.878
  No                                              80 (88.9)     135 (88.2)   
  CEA level (ng/ml) ^c^                                                      
  ≤5                                              40 (44.4)     55 (35.9)    0.190
  \>5                                             50 (55.6)     98 (64.1)    
  CA19-9 level (U/ml) ^d^                                                    
  ≤37                                             61 (67.8)     113 (73.9)   0.310
  \>37                                            29 (32.2)     40 (26.1)    

^a^ Data of 193 patients were available

^b^ Radiofrequency ablation therapy within 3 months before or after hepatic resection

^c^ Carcinoembryonic antigen before hepatic resection

^d^ Cancer antigen 19-9 before hepatic resection

###### 

Univariate and multivariate analyses using Cox proportional hazards models using factors influencing OS and RFS

  Clinicaopathological features               OS univariate analysis   Multivariate analysis   RFS univariate analysis   Multivariate analysis                                                         
  ------------------------------------------- ------------------------ ----------------------- ------------------------- ----------------------- --------------------- --------- --------------------- ---------
                                              HR (95% CI)              P value                 HR (95% CI)               P value                 HR (95% CI)           P value   HR (95% CI)           P value
  **PNI**                                                                                                                                                                                              
  ≤48.5 vs. \>48.5                            0.606 (0.412-0.890)      0.011                   0.574 (0.387-0.851)       0.006                   0.725 (0.528-0.995)   0.046     0.650 (0.472-0.897)   0.009
  **Age (years)**                                                                                                                                                                                      
  ≤60 vs.\>60                                 1.468 (1.002-2.150)      0.049                                                                     1.074 (0.780-1.477)   0.662                           
  **Sex**                                                                                                                                                                                              
  Female vs. Male                             1.323 (0.886-1.977)      0.172                                                                     1.235 (0.891-1.711)   0.205                           
  **Primary tumor site**                                                                                                                                                                               
  Colon vs. Rectum                            1.310 (0.892-1.922)      0.168                                                                     1.100 (0.800-1.514)   0.557                           
  **Primary tumor size (cm) ^a^**                                                                                                                                                                      
  ≤4 vs. \>4                                  0.796 (0.509-1.245)      0.318                                                                     0.798 (0.557-1.142)   0.216                           
  **T stage**                                                                                                                                                                                          
  1-3 vs. 4                                   1.222 (0.824-1.812)      0.320                                                                     1.093 (0.789-1.514)   0.593                           
  **N stage**                                                                                                                                                                                          
  0 vs. 1-2                                   1.505 (1.014-2.234)      0.043                   1.653 (1.110-2.461)       0.013                   1.655 (1.197-2.289)   0.002     1.856 (1.336-2.578)   \<0.001
  **Histological grade**                                                                                                                                                                               
  Well/moderate vs. Poor                      1.295 (0.788-2.130)      0.308                                                                     1.042 (0.674-1.611)   0.853                           
  **Size of liver metastases (cm)**                                                                                                                                                                    
  ≤2.5 vs. \>2.5                              1.428 (0.975-2.092)      0.067                                                                     1.537 (1.125-2.101)   0.007                           
  **Number of liver metastases**                                                                                                                                                                       
  Single vs. Multiple                         1.834 (1.238-2.718)      0.002                   1.940 (1.281-2.938)       0.002                   1.823 (1.325-2.508)   \<0.001   1.750 (1.249-2.452)   0.001
  **Extrahepatic metastasis**                                                                                                                                                                          
  Yes vs. No                                  0.575 (0.321-1.030)      0.063                                                                     0.618 (0.369-1.038)   0.069                           
  **Liver metastasis timing**                                                                                                                                                                          
  Metachronous vs. Synchronous                0.733 (0.500-1.073)      0.110                                                                     0.762 (0.558-1.041)   0.088                           
  **Chemotherapy before hepatic resection**                                                                                                                                                            
  Yes vs. No                                  0.796 (0.534-1.186)      0.262                                                                     0.610 (0.441-0.844)   0.003                           
  **Chemotherapy after hepatic resection**                                                                                                                                                             
  Yes vs. No                                  1.709 (1.118-2.614)      0.013                   1.705 (1.107-2.624)       0.015                   1.162 (0.809-1.668)   0.417                           
  **RFA therapy ^b^**                                                                                                                                                                                  
  Yes vs. No                                  0.523 (0.311-0.881)      0.015                   0.558 (0.323-0.965)       0.037                   0.412 (0.267-0.635)   \<0.001   0.430 (0.273-0.680)   \<0.001
  **CEA level (ng/ml) ^c^**                                                                                                                                                                            
  **≤**5 vs. \>5                              1.249(0.840-1.856)       0.272                                                                     1.453(1.046-2.019)    0.026     1.460(1.046-2.037)    0.026
  **CA19-9 level (U/ml) ^d^**                                                                                                                                                                          
  **≤**37 vs. \>37                            1.446(0.965-2.166)       0.074                                                                     1.191(0.847-1.675)    0.315                           

HR hazard ratio, CI confidence interval

^a^ Data of 193 patients were available

^b^ Radiofrequency ablation therapy within 3 months before or after hepatic resection

^c^ Carcinoembryonic antigen before hepatic resection

^d^ Cancer antigen 19-9 before hepatic resection
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